Patents by Inventor David William End

David William End has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8329714
    Abstract: (?)-5-(3-Chlorophenyl)-?-(4-chlorophenyl)-?-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: December 11, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Gaston Venet, Patrick René Angibaud, David William End
  • Patent number: 8318753
    Abstract: (?)-5-(3-Chlorophenyl)-?-(4-chlorophenyl)-?-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 27, 2012
    Assignee: Janssen Pharmaceutica NV
    Inventors: Marc Gaston Venet, Patrick René Angibaud, David William End
  • Publication number: 20120108634
    Abstract: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.
    Type: Application
    Filed: January 4, 2012
    Publication date: May 3, 2012
    Inventor: David William End
  • Publication number: 20110105557
    Abstract: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.
    Type: Application
    Filed: January 7, 2011
    Publication date: May 5, 2011
    Inventor: David William End
  • Patent number: 7592356
    Abstract: a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(?O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; ?Z1—Z2?Z3— represents a radical of formula ?N—N?CH— (a-1), ?N—CH?N— (a-2), ?CH—N?N— (a-3); X is SO2, (CH2), wherein n is 1 to 4, C(?O), C(?S), or a direct bond; R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: September 22, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ashis Kumar Saha, David William End, Bart Lieven Daniel De Corte, Henry Joseph Breslin, Li Liu
  • Patent number: 7511061
    Abstract: A prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(?O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; =Z1-Z2=Z3- represents a radical of formula ?N—N?CH— (a-1), ?N—CH?N— (a-2), ?CH—N?N— (a-3); X is SO2, (CH2)n wherein n is 1 to 4, C(?O), C(?S), or a direct bond; R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hy
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: March 31, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Ashis Kumar Saha, David William End, Bart Lieven Daniel De Corte, Henry Joseph Breslin, Li Liu
  • Publication number: 20090023776
    Abstract: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.
    Type: Application
    Filed: September 29, 2008
    Publication date: January 22, 2009
    Inventor: David William End
  • Publication number: 20080114009
    Abstract: (?)-5-(3-Chlorophenyl)-?-(4-chlorophenyl)-?-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer
    Type: Application
    Filed: October 29, 2007
    Publication date: May 15, 2008
    Inventors: Marc Gaston Venet, Patrick Rene Angibaud, David William End
  • Patent number: 7253183
    Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula -Alk1-C(?O)—R9, -Alk1-S(O)—R9 or -Alk1-S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently are hydrogen, halo, cyano, C1-6alkyl, 4
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: August 7, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: David William End, Michael J. Zelesko
  • Patent number: 7049324
    Abstract: a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(?O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; ?Z1—Z2?Z3— represents a radical of formula ?N—N?CH— (a-1), ?N—CH?N— (a-2), ?CH—N?N— (a-3); X is SO2, (CH2)n wherein n is 1 to 4, C(?O), C(?S), or a direct bond, R2 is aryl, C3-7cycloalkyl, C3-7cycloalkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalkyl, hydroxycarbonyl, C1-6alkyloxycarbonyl, hydroxyC1-6alkyl, hydroxyC1-6alkyloxy, hydroxyC1-6alkylthio and arylC1-6alkylthio, C1-12alkyl or C1-12alkyl substituted with one or more substituents independently selected from hydroxy, aryl, aryloxy, a substituted or unsubstituted C1-14heterocycle, C3-7cycloalky
    Type: Grant
    Filed: November 15, 2000
    Date of Patent: May 23, 2006
    Inventors: Ashis Kumar Saha, David William End, Bart Lieven Daniel De Corte, Henry Joseph Breslin, Li Liu
  • Patent number: 6838467
    Abstract: This invention relates to a method of treatment and dosing regimen for treating mammalian tumors by the discontinuous administration of a farnesyl transferase inhibitor over an abbreviated one to five day dosing schedule.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: January 4, 2005
    Assignee: Janssen Pharmaceutica N. V.
    Inventor: David William End
  • Publication number: 20040198771
    Abstract: This invention comprises the use of compounds of formula (I) 1
    Type: Application
    Filed: April 14, 2004
    Publication date: October 7, 2004
    Inventors: David William End, Michael J. Zelesko
  • Publication number: 20040157882
    Abstract: This invention comprises the use of compounds of formula (I) 1
    Type: Application
    Filed: June 18, 2003
    Publication date: August 12, 2004
    Inventors: David William End, Michael J. Zelesko
  • Publication number: 20040157773
    Abstract: The present invention relates to the use of farnesyl protein transferase inhibitors for the manufacture of a medicament for the treatment of cachexia.
    Type: Application
    Filed: October 24, 2003
    Publication date: August 12, 2004
    Inventor: David William End
  • Publication number: 20040110769
    Abstract: The present invention is concerned with combinations of a farnesyl transferase inhibitor and an antiestrogen agent for inhibiting the growth of tumor cells, useful in the treatment of cancer.
    Type: Application
    Filed: August 14, 2003
    Publication date: June 10, 2004
    Inventor: David William End
  • Patent number: 6743805
    Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula -Alk1-C(═O)—R9, -Alk1-S(O)—R9 or -Alk1-S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxyC1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6alkyl; R6 and R7 each independently ar
    Type: Grant
    Filed: November 28, 2001
    Date of Patent: June 1, 2004
    Assignee: Janssen Pharmaceutica NV
    Inventors: David William End, Michael J. Zelesko
  • Patent number: 6734194
    Abstract: This invention comprises the use of compounds of formula (I) wherein the dotted line represents an optional bond; X is oxygen or sulfur; R1 is hydrogen, C1-12alkyl, Ar1, Ar2C1-6alkyl, quinolinylC1-6alkyl, pyridylC1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, aminoC1-6alkyl, or a radical of formula —Alk1—C(═O)—R9, —Alk1—S(O)—R9 or —Alk1—S(O)2—R9; R2, R3 and R16 each independently are hydrogen, hydroxy, halo, cyano, C1-6alkyl, C1-6alkyloxy, hydroxyC1-6alkyloxy, C1-6alkyloxy C1-6alkyloxy, aminoC1-6alkyloxy, mono- or di(C1-6alkyl)aminoC1-6alkyloxy, Ar1, Ar2C1-6alkyl, Ar2oxy, Ar2C1-6alkyloxy, hydroxycarbonyl, C1-6alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C2-6alkenyl; R4 and R5 each independently are hydrogen, halo, Ar1, C1-6alkyl, hydroxyC1-6alkyl, C1-6alkyloxyC1-6alkyl, C1-6alkyloxy, C1-6alkylthio, amino, hydroxycarbonyl, C1-6alkyloxycarbonyl, C1-6alkylS(O)C1-6alkyl or C1-6alkylS(O)2C1-6a
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: May 11, 2004
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: David William End, Michael J. Zelesko
  • Publication number: 20040044032
    Abstract: The present invention relates to the use of certain farnesyl protein transferase inhibitors for the manufacture of a medicament for the treatment of inflammatory bowel disease.
    Type: Application
    Filed: May 28, 2003
    Publication date: March 4, 2004
    Inventors: David William End, Charles Ronald Bowden
  • Publication number: 20030229118
    Abstract: This invention comprises the use of compounds of formula (I) 1
    Type: Application
    Filed: June 18, 2003
    Publication date: December 11, 2003
    Inventors: David William End, Michael J. Zelesko
  • Publication number: 20030114471
    Abstract: (−)-5-(3-Chlorophenyl)-&agr;-(4-chlorophenyl)-&agr;-(1-methyl-1H-imidazol-5-yl)tetrazolo-[1,5-a]quinazoline-7-methanamine and its pharmaceutically acceptable acid addition salts, and the use of such compounds in medicine especially for the treatment of cancer
    Type: Application
    Filed: December 20, 2002
    Publication date: June 19, 2003
    Inventors: Marc Gaston Venet, Patrick Rene Angibaud, David William End